Tag: Limited distribution

In 2021, the FDA granted Tavneos (avacopan) orphan drug designation for treating the rare autoimmune condition ANCA-associated vasculitis. This designation and subsequent distribution model answer the question: Is avacopan a specialty drug? Yes, avacopan is officially a specialty medication, a designation that impacts its access, handling, and cost for patients.

Over 50% of pharmaceutical spending in the U.S. is projected to be on specialty drugs, even though they are used by a smaller percentage of the population. This trend highlights the growing number of high-cost, high-touch therapies, prompting many to ask: is TYVASO a specialty med?